Clinical trials: Tenofovir, open to volunteers
Tenofovir, Tenofovir Alafenamide Fumarate
Tenofovir Exposures in Advanced Kidney Disease Study
Phamacokinetic study to evaluate tenofovir, emtricitabine and tenofovir alafenamide exposures in people with HIV who have chronic kidney disease stage 4 (estimated glomerular filtration rate [eGFR] 15-29 mL/min/1.73m2) or stage 3…
- Conditions
- Tenofovir, Tenofovir Alafenamide Fumarate, Chronic Kidney Diease, Kidney Failure
- Trial name
- TEAK (NCT07812571)
- Testing
- Plasma sampling for tenofovir and emtricitabine, Descovy
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- King's College Hospital NHS Trust
Chronic Hepatitis b, Tenofovir Alafenamide Fumarate
Study of Tenofovir Alafenamide in HBV-Infected Pregnant Women
The purpose of this study is to evaluate the pharmacokinetics, efficacy and safety of TAF in HBV-infected pregnant women.
- Trial name
- NCT05853718
- Testing
- Tenofovir Alafenamide Tablets
- Where
- China
- Volunteers
- 50 people
- Sponsor
- First People's Hospital of Hangzhou
EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor
Application of PD-1 Inhibitors, Tenofovir, Chidamide, and Lenalidomide in Relapsed/Refractory EBV-associated Lymphoproliferative Disorders.
This study is a prospective, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of PD-1 inhibitor combined with tenofovir, chidamide, and lenalidomide in the treatment of relapsed or refractory…
- Conditions
- EBV-Associated Lymphoproliferative Disorders, PD-1 Inhibitor, Tenofovir, Chidamide
- Trial name
- NCT07133763
- Testing
- PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV-Associated Lymphoproliferative Disorders.
- Volunteers
- 50 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
Currently, treatment options for Epstein-Barr virus (EBV) infection are limited, with unsatisfactory efficacy and no established standard therapy.
- Conditions
- Epstein-Barr Virus (EBV) Infection, PD-1 Inhibitor, Tenofovir, Chidamide
- Trial name
- NCT07133776
- Testing
- PD-1 Inhibitor Combined with Tenofovir, Chidamide, and Lenalidomide for the Treatment of EBV Infectious Diseases.
- Volunteers
- 30 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Tenofovir Disoproxil Fumarate, Bone Density
Effect of Long-Term Use of Tenofovir (TDF) on Bone Density in Patients With Chronic Hepatitis B
This study aims to evaluate the effect of long-term use of Tenofovir Disoproxil Fumarate (TDF) on bone density in patients with chronic hepatitis B virus (HBV) infection.
- Conditions
- Tenofovir Disoproxil Fumarate, Bone Density, Chronic HBV Infection
- Trial name
- NCT06990438
- Testing
- TDF (Tenofovir)
- Where
- Egypt
- Volunteers
- 172 people
- Sponsor
- Assiut University
Tenofovir Disoproxil Fumarate, Renal Function Disorder
Effect of Tenofovir (TDF) on Renal Function in Patients With Chronic Hepatitis B
Effect of Long-Term Use of Tenofovir (TDF) on Renal Function in Patients with Chronic Hepatitis B Over a Five-Year Period
- Conditions
- Tenofovir Disoproxil Fumarate, Renal Function Disorder, Chronic HBV Infection
- Trial name
- NCT06896630
- Testing
- Tenofovir Disoproxil Fumarate (TDF)
- Where
- Egypt
- Volunteers
- 172 people
- Sponsor
- Assiut University